Voyager Acquisition Corp. (VACH) to Combine with VERAXA Biotech in $1.3Bn Deal
Voyager (NASDAQ:VACH) has signed a definitive agreement to combine with biotech firm VERAXA at an enterprise value of $1.38 billion. Heidelberg, Germany-based VERAXA is developing cancer treatments with its most advanced candidate targeting acute myeloid leukemia (AML). The combined company is expected to trade on the Nasdaq under the symbol “VERX” once the deal is
Read More
To access this post, you must purchase 1 - User: Monthly Plan.